- Trials with a EudraCT protocol (156)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
156 result(s) found for: Protein Domain.
Displaying page 1 of 8.
EudraCT Number: 2020-000769-18 | Sponsor Protocol Number: EFC16295 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-X... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) HU (Completed) NL (Completed) IT (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004399-42 | Sponsor Protocol Number: C87037 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:UCB Japan Co., Ltd. | |||||||||||||
Full Title: A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With... | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002436-82 | Sponsor Protocol Number: EC11-441 | Start Date*: 2012-12-13 |
Sponsor Name:Isabel Pinilla Lozano | ||
Full Title: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa | ||
Medical condition: To evaluate the sleep quality in patients with Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002023-15 | Sponsor Protocol Number: EFC16293 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. (a Sanofi company) | |||||||||||||
Full Title: Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTE... | |||||||||||||
Medical condition: severe hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) BG (Completed) BE (Completed) GR (Completed) HU (Completed) NL (Completed) ES (Completed) Outside EU/EEA IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004354-34 | Sponsor Protocol Number: C87047 | Start Date*: 2015-02-27 | |||||||||||
Sponsor Name:UCB Japan Co., Ltd. | |||||||||||||
Full Title: A 26-week, multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s disease patients, who showed clinical efficacy in a remission induction study (Study C87... | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008200-40 | Sponsor Protocol Number: VGFT-OD-0706 | Start Date*: 2009-05-20 |
Sponsor Name:Regeneron Pharmaceuticals, Inc | ||
Full Title: A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME) | ||
Medical condition: Diabetic Macular Edema (DME) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004216-22 | Sponsor Protocol Number: C602 | Start Date*: 2019-09-25 | |||||||||||
Sponsor Name:Soleno Therapeutics UK Ltd. | |||||||||||||
Full Title: An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome | |||||||||||||
Medical condition: Hyperphagia associated with Prader-Willi Syndrome (PWS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006574-23 | Sponsor Protocol Number: AR101-PREVEnt | Start Date*: 2022-08-30 | |||||||||||
Sponsor Name:Aytu BioPharma, Inc. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 ... | |||||||||||||
Medical condition: vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) BE (Ongoing) FR (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001004-15 | Sponsor Protocol Number: A1334-02 | Start Date*: 2022-04-22 | |||||||||||||||||||||||||||||||
Sponsor Name:ACCELERON PHARMA INC. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1b/2 Open-Label, Multiple-Ascending Dose Study Followed by a Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Effica... | |||||||||||||||||||||||||||||||||
Medical condition: Systemic sclerosis (SSc), a rare connective tissue disorder characterized by fibrosis, inflammation, and microvascular injury with heterogeneous presentations; Interstitial lung disease (ILD), a co... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000976-40 | Sponsor Protocol Number: ION373-CS1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand... | |||||||||||||
Medical condition: Alexander Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000975-21 | Sponsor Protocol Number: RET-AFLI-2014-01 | Start Date*: 2014-06-16 |
Sponsor Name:Fundación Retinaplus + | ||
Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ... | ||
Medical condition: Macular edema secondary to central retinal vein occlusion. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000300-10 | Sponsor Protocol Number: IDI-AFLI-2013-01 | Start Date*: 2014-04-23 |
Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL) | ||
Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study. | ||
Medical condition: Retinal angiomatous proliferation lesions (RAP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000814-23 | Sponsor Protocol Number: CLDK378A2407 | Start Date*: 2015-10-26 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphom... | ||
Medical condition: Advanced solid tumors and hematological malignancies with ALK genetic alteration and/or overexpression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Temporarily Halted) CZ (Completed) FR (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-004400-30 | Sponsor Protocol Number: C87048 | Start Date*: 2015-02-27 | |||||||||||
Sponsor Name:UCB Japan Co., Ltd. | |||||||||||||
Full Title: A multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s Disease patients, who showed no clinical efficacy in a remission induction study (Study C87037) b... | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004066-19 | Sponsor Protocol Number: CV-NCOV-005 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:CureVac AG | |||||||||||||
Full Title: COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care ... | |||||||||||||
Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001831-30 | Sponsor Protocol Number: ISIS420915-CS2 | Start Date*: 2013-04-22 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy | |||||||||||||
Medical condition: Familial Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000562-36 | Sponsor Protocol Number: BIG2-06/N063D/EGF106708 | Start Date*: 2007-05-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb... | |||||||||||||
Medical condition: Operable primary breast cancer with over expression/ amplification of HER2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004070-22 | Sponsor Protocol Number: CV-NCOV-003 | Start Date*: 2021-04-12 | |||||||||||
Sponsor Name:CureVac AG | |||||||||||||
Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi... | |||||||||||||
Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002715-38 | Sponsor Protocol Number: APHP220775 | Start Date*: 2023-03-20 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech... | ||
Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.